How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cell Processing Kit Market
- By Kit Type: Cell Isolation Kits, Cell Culture Kits, Cell Labeling Kits, Cell Counting Kits, Cell Viability Kits
- By Application: Stem Cell Research, Immunotherapy, Cancer Research, Regenerative Medicine, Drug Discovery
- By End User: Research Laboratories, Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Contract Research Organizations (CROs)
- By Cell Type: Hematopoietic Cells, Mesenchymal Stem Cells, T Cells, Dendritic Cells, Induced Pluripotent Stem Cells (iPSCs)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cell Isolation Kits leads By Kit Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Cell Processing Kit Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Kit Type 5
Application 5
End User 5
Cell Type 5
Companies profiled
Thermo Fisher Scientific
Miltenyi Biotec
Sartorius AG
Lonza Group
GE Healthcare Life Sciences (now Cytiva)
BD (Becton
Dickinson and Company)
Corning Incorporated
Merck KGaA (MilliporeSigma)
Bio-Rad Laboratories
STEMCELL Technologies
Cytiva
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Miltenyi Biotec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Lonza Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GE Healthcare Life Sciences (now Cytiva)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →BD (Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Dickinson and Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Corning Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Merck KGaA (MilliporeSigma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bio-Rad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →STEMCELL Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cytiva
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →NantKwest
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →CellGenix
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Repligen Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Asahi Kasei Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,234M by 2033 · 9.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cell Isolation Kits54.7
- Cell Culture Kits13.8
- Cell Labeling Kits6.4
- Cell Counting Kits14.2
- Cell Viability Kits10.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$346.1M → $721.3M · 9.6%
Europe$241.2M → $457.5M · 8.3%
Asia Pacific$220.3M → $505.9M · 11.0%
Latin America$136.4M → $316.0M · 11.1%
Middle East and Africa$104.9M → $229.6M · 10.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.862026
9.882027
9.892028
9.912029
9.912030
9.922031
9.952032
9.942033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific21.8
- Miltenyi Biotec24.6
- Sartorius AG9.4
- Lonza Group5.0
- GE Healthcare Life Sciences (now Cytiva)5.4
- BD (Becton5.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Kit Type25.6%
Application17.7%
End User40.5%
Cell Type16.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe20.5
- Asia Pacific22.7
- Latin America14.2
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 97 | 89 | 80 | 89 | 77 | 95 | 88 |
| Miltenyi Biotec | 92 | 84 | 74 | 86 | 78 | 69 | 81 |
| Sartorius AG | 85 | 74 | 66 | 80 | 69 | 86 | 77 |
| Lonza Group | 58 | 75 | 59 | 73 | 64 | 81 | 68 |
| GE Healthcare Life Sciences (now Cytiva) | 67 | 69 | 60 | 71 | 65 | 72 | 67 |
| BD (Becton | 56 | 48 | 63 | 64 | 56 | 48 | 56 |
| Dickinson and Company) | 59 | 50 | 54 | 46 | 65 | 64 | 56 |
| Corning Incorporated | 51 | 39 | 54 | 47 | 54 | 45 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Miltenyi Biotec
- Sartorius AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Miltenyi Biotec | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Sartorius AG | ◐ | ◐ | − | ✓ | ◐ | ✓ |
| Lonza Group | − | ✓ | ◐ | ✓ | ◐ | ✓ |
| GE Healthcare Life Sciences (now Cytiva) | ◐ | ◐ | − | − | ◐ | ✓ |
| BD (Becton | − | − | ◐ | − | ◐ | − |
| Dickinson and Company) | ◐ | − | ◐ | − | − | ◐ |
| Corning Incorporated | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific88
2Miltenyi Biotec81
3Sartorius AG77
4Lonza Group68
5GE Healthcare Life Sciences (now Cytiva)67
6BD (Becton56
7Dickinson and Company)56
8Corning Incorporated48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificMiltenyi Biotec
Challenger3
Strong scale, closing on the leaders.
Sartorius AGLonza GroupGE Healthcare Life Sciences (now Cytiva)
Niche3
Specialists in a single segment or region.
BD (BectonDickinson and Company)Corning Incorporated
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Kit Type in North America, then scale across Cell Processing Kit Market — a $74M beachhead inside a $1.03B market.
Beachhead (SOM)$74Mobtainable near-term
Serviceable (SAM)$418Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Cell Isolation Kits
Best fit — highest urgency & budget in Kit Type.
Economic buyer75 fit
Cell Culture Kits
Strong fit — clear ROI and a fast path to value.
End user68 fit
Cell Labeling Kits
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Kit Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel27%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Kit Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cell Processing Kit Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation14%
Closed-won6%
$21.3KCAC
$117KLTV
5.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cell Processing Kit Market is a durable-growth opportunity — $7.69B by 2033, compounding at 6.5%.
TAM · 2025$4.66Btoday
TAM · 2033$7.69Bforecast
CAGR6.5%2027–2033
Cumulative$54.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.69BTotal addressable market
SAM$3.01BServiceable available market
SOM$585MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.5% CAGR
Demand compounds through 2033, outpacing GDP across Kit Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Kit Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.69BLarge & growingTAM by 2033 at 6.5% CAGR
$3.01BServiceable nowreachable with today’s model
$585MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.00BBear4.2% CAGR
$7.69BBase6.5% CAGR
$9.85BBull8.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cell Processing Kit Market — a $9.10B market by 2033. Plan: grow share from 8.3% to 15.9%.
Market size · 2033$9.10Btotal addressable
Market CAGR7.9%2027–2033
Target share15.9%from 8.3% today
Revenue ambition$1.45Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 15.9% | Ahead |
| Revenue | $711M | $1.45B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 32.0% | 38.3% | On track |
| Customer retention | 86.5% | 92.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Kit Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Kit Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $161M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Kit Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cell Processing Kit Market conversation — a $4.61B market you can size, segment and defend in minutes.
Market size · 2033$4.61Btotal opportunity
Growth7.4%CAGR to 2033
Addressable buyers944+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Kit Type
Goal Grow share in Kit Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 3 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Thermo Fisher ScientificMiltenyi BiotecSartorius AGLonza GroupGE Healthcare Life Sciences (now Cytiva)BD (BectonDickinson and Company)Corning Incorporated+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cell Processing Kit Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cell Processing Kit Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cell Processors Market
Market size, share, segmentation and regional forecast.
$494M market · 2025 base year
View reportCell Proliferation Assay Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCell Reactor Market
Market size, share, segmentation and regional forecast.
$553M market · 2025 base year
View reportCell Reprogramming Technology Market
Market size, share, segmentation and regional forecast.
$783M market · 2025 base year
View reportCell RNA Detection Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportCell Separator Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportCell Sorters Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCell Sorting Equipment Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCell STR Identification Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCell Structure Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportCell Tester Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCell Turn-Key Production Line Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.